ClinicalTrials.gg
Enrolling by invitationNCT07443202Updated Mar 2, 2026

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

A Phase 2 interventional study of lotilaner and Vehicle in Ocular Rosacea, sponsored by Tarsus Pharmaceuticals, Inc.. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Tarsus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.

Planned enrollment
50th of 137
155 · median 78
Started
2025
with 2 others
Phase 2
35 of 145
4 open now
Registered
142nd of 145
by date

Among the 145 studies in Rosacea with a site in United States, this one is the 50th largest by planned enrollment of the 137 interventional ones that give a count, is one of 3 that started in 2025, is one of 35 in phase 2, and was the 142nd registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

To evaluate lotilaner treatment in patients with ocular rosacea.

Read the detailed description

To evaluate safety of lotilaner compared to vehicle control in the treatment of ocular rosacea.

03

Conditions studied

  • Ocular Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older at the time of consent.
  • Has moderate to severe ocular rosacea
  • Use of acceptable methods of
  • Are willing to sign the form and is deemed capable of complying with the requirements of the study protocol

Exclusion criteria

Exclusion Criteria:

  • Patient taking a topical or other therapy which may affect the patients rosacea
  • Actively managed glaucoma or active ocular infection or ocular systemic disease
  • Have to lotilaner or any of the formulation components
  • Are currently enrolled in an drug or device study
  • Are currently pregnant or lactating or planning to become pregnant during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Treatment arm

    lotilaner - high dose and low dose

    Drug: lotilaner

  • Other
    Control arm

    Vehicle of lotilaner - high dose and low dose

    Drug: Vehicle

Interventions

  • lotilaner

  • DrugVehicle

    Vehicle of lotilaner

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events

    Number of patients with treatment related emergent adverse events (TEAEs)

    Time frame: Week 16

Secondary outcomes

  1. Intraocular pressure

    Measurement of intraocular pressure

    Time frame: Week 16

  2. Visual acuity

    Measurement of visual acuity

    Time frame: Week 16

Other outcomes

  1. Telangiectasia

    Grading of telangiectasia

    Time frame: Week 16

  2. Erythema

    Grading of erythema

    Time frame: Week 16

07

Study locations

2 sites
  • Site
    Houston, Texas 77027, United States
  • Site
    Lynchburg, Virginia 24502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 20 phase 2 interventional studies under Rosacea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Dec 5, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07443202
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Dec 5, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lotilaner

Start the discussion